Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Aoxing Pharmaceutical has reported that the China State Food & Drug Administration has granted the company designated manufacturer status to produce Tilidine tablets and capsules, a highly regulated narcotic drug, for the treatment of cancer pain in China.
Subscribe to our email newsletter
Tilidine is a prodrug, which, following oral administration, is converted to the active analgesic metabolite, nortilidine. Tilidine is indicated for the relief of acute, moderate to severe pain, and chronic cancer-related pain. Currently Tilidine is not available in China and will be introduced by China Aoxing to the China market.
Zhenjiang Yue, the CEO of CAXG, said: “We expect to launch this important and needed cancer pain medicine through CAXG’s integrated 500-person sales force in later 2008. Our mission is to bring multiple effective therapeutic options, including Oxycodone, Tilidine and other promising narcotic pain medicines in our pipeline, to help approximately 20 million cancer patients in China.”